JUN MATSUSHITA

Real-world Feasibility of Adjuvant Nivolumab for High-risk Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy

Background/Aim: Adjuvant nivolumab is an important postoperative option for high-risk muscle-invasive urothelial carcinoma, but upper tract urothelial carcinoma (UTUC)-specific real-world evidence remains limited. This study evaluated oncologic outcomes, feasibility, and safety o...